Cost and Impact on Patient Length of Stay of Rapid Molecular Testing for Clostridium difficile

Infectious Diseases and Therapy

Volumn 3, Issue 2, 2014, Pages 281-293

  Sewell, Bernadette ^a   Rees, Eugene ^b   Thomas, Ian ^b   Ch’ng, Chin Lye ^b   Isaac, Mike ^b   Berry, Nidhika ^b  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b SINGLETON HOSPITAL   (United Kingdom)

Author keywords

Cell culture cytotoxin neutralization assay; Clostridium difficile; Cost comparison; Length of hospital stay; Polymerase chain reaction (PCR); Rapid molecular testing; Xpert PCR

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN B; GLUTAMATE DEHYDROGENASE;

AGE; AGED; ARTICLE; BIOASSAY; CLINICAL PROTOCOL; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CYTOTOXICITY ASSAY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME IMMUNOASSAY; FECES ANALYSIS; FEMALE; GENDER; HEALTH CARE COST; HEALTH IMPACT ASSESSMENT; HEALTH SERVICE; HOSPITAL; HOSPITAL INFORMATION SYSTEM; HUMAN; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NURSE; PATIENT CARE; POLYMERASE CHAIN REACTION; REACTION TIME; SENSITIVITY AND SPECIFICITY;

CLOSTRIDIUM DIFFICILE;

EID: 84977107261     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-014-0034-x     Document Type: Article

References (39)

1. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145:758–64.
2. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol. 2009;30:57–66.
3. McGlone SM, Bailey RR, Zimmer SM, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect. 2012;18:282–9.
4. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346–53.
5. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46:497–504.
6. Wilcox MH, Cunniffe JG, Trundle C, Redpath C. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect. 1996;34:23–30.
7. Vonberg RP, Reichardt P, Behnke M, Schwab F, Zindler S, Gastmeier P. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect. 2008;70:15–20.
8. Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ. 2012;184:37–42.
9. Campbell R, Dean B, Nathanson B, Haidar T, Strauss M, Thomas S. Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-associated diarrhea. J Med Econ. 2013;16:440–8.
10. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol. 2008;29:823–8.
11. Chapin KC, Dickenson RA, Wu F, Andrea SB. Comparison of five assays for detection of Clostridium difficile toxin. J Mol Diagn. 2011;13:395–400.
12. Planche T, Wilcox M. Reference assays for Clostridium difficile infection: one or two gold standards? J Clin Pathol. 2011;64:1–5.
13. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.
14. Quinn CD, Sefers SE, Babiker W, et al. C. Diff Quik Chek Complete Enzyme Immunoassay Provides a Reliable First-Line Method for detection of Clostridium difficile in Stool Specimens. J Clin Microbiol. 2010;48:603–5.
15. Novak-Weekley SM, Marlowe EM, Miller JM, et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J Clin Microbiol. 2010;48:889–93.
16. Reller M, Alcabasa RC, Lema CA, Carroll KC. Comparison of two rapid assays for Clostridium difficile common antigen and a C difficile toxin A/B assay with the cell culture neutralization assay. Microbiol Infect Dis. 2010;133:107–9.
17. Berry N, Sewell B, Jafri S, Puli C, Vagia S, Lewis AM, Davies D, Rees E, Ch’ng CL. Real-time polymerase chain reaction correlates well with clinical diagnosis of Clostridium difficile infection. J Hosp Infect. 2014;87(2):109–14.
18. Department of Health. NHS reference costs 2010-2011. Department of Health 2012, United Kingdom. http://data.gov.uk/dataset/nhs-reference-costs-2010-11 Accessed Feb 2012.
19. Welsh Healthcare Associated Infection Programme. Clostridium difficile. Mandatory Surveillance Report. Abertawe Bro Morgannwg University Health Board. Public Health Wales. 2012. http://www2.nphs.wales.nhs.uk:8080/WHAIPDocs.nsf/3dc04669c9e1eaa880257062003b246b/87239a685280fb9680257a4f0035fc37/$FILE/ABMU%20Report%20Apr%2011%20-%20Mar%2012.pdf Accessed Jul 2012.
20. Gerding DN, Muto CA, Owens RC. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis. 2008;46:S43–9.
21. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81:1–14.
22. Al-Eidan FA, McElnay JC, Scott MG, Kearney MP. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Pharm Ther. 2000;25:101–9.
23. Casari E, Ferrario A, De Luca C, Calabro M, Allibardi S, Lagioia M. Improvement in patient management through the use of a Clostridium difficile PCR real time stand alone test in acute hospital setting. In: Program and Abstracts of the 52nd International Congress of Antimicrobial Agents and Chemotherapy (ICAAC); September 9–12, 2012; San Francisco, CA. Abstract D-159.
24. Bartsch SM, Curry SR, Harrison LH, Lee BY. The potential economic value of screening hospital admissions for Clostridium difficile. Eur J Clin Microbiol Infect Dis. 2012;31:3163–71.
25. Brown J, Paladino JA. Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalised patients with bacteraemia. Pharmacoeconomics. 2010;28:567–75.
26. Lehmann LE, Herpichboehm B, Kost GJ, Koller MH, Stueber F. Cost and mortality prediction using polymerase chain reaction pathogen detection in sepsis: evidence from three observational trials. Crit Care. 2010;14:R186.
27. Nigrovic LE, Chiang VW. Cost analysis of enteroviral polymerase chain reaction in infants with fever and cerebrospinal fluid pleocytosis. Arch Pediatr Adolesc Med. 2000;154:817–21.
28. Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol. 2009;47:3211–7.
29. Sloan LM, Duresko BJ, Gustafson DR, Rosenblatt JE. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol. 2008;46:1996–2001.
30. Humphries RM, Uslan DZ, Rubin Z. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol. 2013;51(3):869–73.
31. Guerrero DM, Chou C, Jury LA, Nerandzic MM, Cadnum JC, Donsky CJ. Clinical and infection control implications of Clostridium difficile infection with negative enzyme immunoassay for toxin. Clin Infect Dis. 2011;53:287–90.
32. Stahlmann J, Schoenberg M, Herrmann M, von Mueller L. Detection of nosocomial Clostridium difficile infections with toxigenic strains despite negative toxin A and B testing on stool samples. Clin Microbiol Infect. 2014; Jan 23. doi: 10.1111/1469-0691.12558.
33. Walker AS, Eyre DW, Wyllie DH, et al. Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med. 2012;9:e1001172.
34. Lanzas C, Dubberke ER, Lu Z, Reske KA, Gröhn YT. Epidemiological model for Clostridium difficile transmission in healthcare settings. Infect Contr Hosp Epidemiol. 2011;32:553–61.
35. Huang H, Weintraub A, Fang H, Nord CE. Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of Clostridium difficile infections. J Clin Microbiol. 2009;47:3729–31.
36. Buchan BW, Mackey T-LA, Daly JA, et al. Multicenter clinical evaluation of the Portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile in clinical stool specimens. J Clin Microbiol. 2012;50:3932–6.
37. Napierala M, Munson E, Skonieczny P, et al. Impact of toxigenic Clostridium difficile polymerase chain reaction testing on the clinical microbiology laboratory and inpatient epidemiology. Diagn Microbiol Infect Dis. 2013;76:534–8.
38. Grein JD, Ochner M, Hoang H, Jin A, Morgan MA, Murthy AR. Comparison of testing approaches for Clostridium difficile infection at a large community hospital. Clin Microbiol Infect. 2014;20:65–9.
39. Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis. 2013;13:936–45.